Edition:
United Kingdom

People: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

81.59USD
16 Jul 2019
Change (% chg)

$0.63 (+0.78%)
Prev Close
$80.96
Open
$81.36
Day's High
$81.78
Day's Low
$80.89
Volume
2,367,546
Avg. Vol
3,366,739
52-wk High
$87.07
52-wk Low
$62.09

Frazier, Kenneth 

Mr. Kenneth C. Frazier is Chairman of the Board, President and Chief Executive Officer of the Company. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company (2009 to 2010) and Merck Sharp & Dohme Corp. (2007 to 2009). Mr. Frazier also served as Executive Vice President and General Counsel (2006 to 2007) of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.). Director, Exxon Mobil Corporation since 2009 and Pharmaceutical Research and Manufacturers of America (PhRMA) since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA; Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association. Mr. Frazier has broad managerial and operational expertise and deep institutional knowledge, as well as a track record of achievement, integrity and sound judgment demonstrated prior to, and during his long tenure with Merck. In addition, his role as the Chair of the Board Affairs Committee of Exxon Mobil Corporation has provided him with important experience on governance issues facing public companies.

Basic Compensation

Total Annual Compensation, USD 4,672,380
Restricted Stock Award, USD 9,456,010
Long-Term Incentive Plans, USD --
All Other, USD 6,806,120
Fiscal Year Total, USD 20,934,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 787,792 26,473,100.00